Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAR113244 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SAR113244 cohort 1 | EXPERIMENTAL | Two administrations of dosage 1 SAR113244 or placebo subcutaneous dose (Q4 weeks) |
| SAR113244 cohort 2 | EXPERIMENTAL | Two administrations of dosage 2 SAR113244 or placebo subcutaneous dose (Q4 weeks) |
| SAR113244 cohort 3 | EXPERIMENTAL | Two administrations of dosage 3 SAR113244 or placebo subcutaneous dose (Q4 weeks) |
| Name | Type | Description |
|---|---|---|
| SAR113244 | DRUG | Pharmaceutical form:solution for injection Route of administration: subcutaneous |
| placebo | DRUG | Pharmaceutical form:solution for injection Route of administration: subcutaneous |
Inclusion criteria: * Male or female patients, between 18 and 75 years of age, inclusive. * Clinical diagnosis of systemic lupus erythematosus (SLE) by American College Rheumatology criteria. * Autoantibody-posititve. * On active and stable SLE disease. Exclusion criteria: * Pregnant and nursing....
Top 20 of 32 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Biogen Inc. | BIIB | 5 | PHASE3 | Litifilimab |
| Bristol-Myers Squibb Company | BMY | 7 | PHASE3 | Deucravacitinib |
| Viatris, Inc. | VTRS | 5 | PHASE3 | Cenerimod |
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Ianalumab |
| AstraZeneca PLC | AZN | 21 | PHASE3 | Medi-546 |
| Johnson & Johnson | JNJ | 1 | PHASE3 | Nipocalimab |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Upadacitinib |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Belimumab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | SAR441344 |
| Zenas BioPharma, Inc. | ZBIO | 1 | PHASE2 | Obexelimab |
| Alumis Inc. | ALMS | 1 | PHASE2 | Envudeucitinib |
| Immunovant Inc | IMVT | 1 | PHASE2 | IMVT-1402 |
| Amgen Inc. | AMGN | 1 | PHASE2 | Inebilizumab, Blinatumomab |
| Fate Therapeutics, Inc. | FATE | 2 | PHASE2 | FT819 |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY4298445 |
| Cartesian Therapeutics, Inc. | RNAC | 2 | PHASE2 | Descartes-08 |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-1045 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE1 | KITE-363, Fludarabine, Cyclophosphamide |
| Artiva Biotherapeutics, Inc. | ARTV | 2 | PHASE1 | AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab |
| Cullinan Therapeutics, Inc. | CGEM | 1 | PHASE1 | CLN-978 |
SAR113244 is an investigational small molecule being developed for the treatment of Systemic Lupus Erythematosus (SLE). It is currently in Phase 1 clinical development and has been studied in a completed multiple ascending dose trial in lupus patients.
SAR113244 is being developed by Sanofi, a multinational pharmaceutical company traded on the stock exchange under the ticker SNY. The drug is an investigational small molecule in Phase 1 clinical development for Systemic Lupus Erythematosus.
SAR113244 is in Phase 1 clinical development. It has completed one Phase 1 trial, and no active trials are currently listed. The drug is investigational and has not been approved by regulatory authorities.
SAR113244 has been studied in one completed Phase 1 clinical trial, identified as NCT02321709. This was a multiple ascending dose study to assess the safety profile of SAR113244 versus placebo in male and female lupus patients, conducted in Germany with 21 participants.
SAR113244 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Systemic Lupus Erythematosus. The only trial conducted, NCT02321709, has been completed, but the drug remains in early-stage clinical testing.